Seaport Therapeutics to present on Thursday, December 11, 2025 at 10:00 AM EST.
Seaport Therapeutics presents at Stifel 2025 Healthcare Conference
Seaport Therapeutics presents at Oppenheimer Private Life Sciences Company Showcase 2025
Optimizing Triglyceride Prodrugs of a Model Immunomodulator: Conjugation through the Phenol of Mycophenolic Acid (MPA) Markedly Promotes Lymphatic Drug Transport
Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity
Triglyceride-Mimetic Prodrugs of Buprenorphine Enhance Oral Bioavailability via Promotion of Lymphatic Transport
SPT-320, a First-in-Class Prodrug of Agomelatine that Avoids
First-Pass Hepatic Metabolism via Lymphatic System Absorption
Clinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials
First-in-human Translation of a Biomimetic Glyceride Prodrug Platform: Enabling Avoidance of First-pass Metabolism via Lymphatic Absorption
101 Seaport Blvd, Boston, MA 02210
General info: info@seaporttx.com
Media: publicrelations@seaporttx.com
101 Seaport Blvd, Boston, MA 02210
General info: info@seaporttx.com
Media: publicrelations@seaporttx.com